What are the most valuable Pet Tech startups?

Top startups in the Pet Tech market ranked by valuation

Here is an updated table that ranks the top startups in the Pet Tech market based on their latest reported or estimated valuations.

If you need to dig deeper and get more detailed data, please check our report covering the Pet Tech market.

Is Rover still the most valuable Pet Tech company?

Yes. Rover remains the most valuable Pet Tech company in this ranking by a wide margin, with Blackstone's completed acquisition valuing the business at about $2.3 billion.

This is one of the cleanest numbers in the entire market because we are dealing with an actual cash transaction rather than a valuation model. Blackstone paid $11 per Rover share when it completed the deal, taking the pet-care marketplace private.

No other company in our dataset currently has equally strong evidence supporting a valuation above $2 billion. Even Whisker, which has built one of the largest independent businesses in the sector, sits much closer to $1 billion based on its revenue and the multiples we can reasonably apply.

Rover's lead also shows how powerful marketplace economics can become once enough supply and demand sit on the same platform. Rover connects pet owners with sitters and walkers without carrying the property, medical equipment or hardware inventory required by several other large Pet Tech companies.

That $2.3 billion figure remains the benchmark everyone else in Pet Tech has yet to reach.

How many Pet Tech unicorns are there today?

Pet Tech currently has very few clear unicorns: Rover is comfortably above $1 billion, while Whisker and Loyal sit around the threshold rather than safely beyond it.

This is where using valuation ranges matters. Whisker generates more than $300 million in annual revenue, so a roughly $900 million to $1.2 billion valuation is defensible. We still do not have a recent financing or acquisition that fixes its value at exactly $1 billion or more.

Loyal is even harder to put into a binary unicorn bucket. The company raised a $100 million Series C recently and has now raised more than $250 million, but most of its value comes from the future commercial potential of canine longevity drugs. Our $800 million to $1.1 billion range reflects that upside as well as the remaining regulatory risk.

Tractive gives us a useful reality check just below them. Bending Spoons disclosed a $759 million enterprise value for the acquisition. That puts one of the world's largest connected pet-tracking companies below the unicorn mark despite substantial scale.

So the sector has one unquestionable unicorn in this ranking and a couple of companies close enough to make the next step plausible. It does not have a deep bench of billion-dollar startups.

Company	Current valuation position	$1B status
Rover	$2.3B	Confirmed above $1B
Whisker	$900M–$1.2B estimated	Around the threshold
Loyal	$800M–$1.1B estimated	Around the threshold
Tractive	$759M acquisition EV	Below $1B
Petvisor	$550M–$850M estimated	Below $1B
SantéVet	$450M–$700M estimated	Below $1B
Petkit	$450M–$650M estimated	Below $1B
Fi	$400M–$600M estimated	Below $1B
Lassie	about $400M	Below $1B
Modern Animal	$399.8M acquisition	Below $1B

Why are veterinary healthcare companies worth so much in Pet Tech?

Veterinary healthcare has become one of the biggest sources of value in Pet Tech because startups can tap directly into recurring medical spending rather than rely on occasional gadget purchases.

The size of that spending is substantial. The American Pet Products Association's current industry statistics put U.S. veterinary care and product sales at about $41 billion. Chewy, when announcing its Modern Animal deal, described veterinary services alone as an approximately $40 billion market growing around 5% a year.

Startups are attacking that spending from several angles. Modern Animal built physical clinics plus virtual care and memberships. Petfolk combines clinics with app-based access. Vetic has expanded to 65 clinics in India and uses those locations for veterinary care, pharmacy and product fulfillment.

Other companies stay on the software side. Petvisor says its products serve more than 10,000 veterinary clinics and hundreds of grooming businesses. Digitail sells AI-powered practice-management software. Lupa wants to become the operating system used inside the clinic. Scribenote focuses on clinical documentation.

Then there are companies such as Loyal and Gallant, where the product is the treatment itself. Successful veterinary drugs and regenerative therapies can reach a completely different level of economics from an appointment-booking app.

That mix is why veterinary healthcare now occupies so much of the upper half of the ranking. There are simply more ways to capture meaningful recurring revenue around animal health than there are around a standalone consumer device.

Are pet insurance startups worth more than pet hardware companies?

Pet insurance has produced more companies in the $100 million to $700 million range, while the very best connected-hardware businesses can still be worth more.

Lassie's latest financing is a good example of how far digital pet insurance has come. The company raised $75 million after reaching roughly $100 million of annual recurring revenue and was valued around $400 million. SantéVet is larger by revenue, while ManyPets, Dalma, Napo, Figo and Wagmo add depth further down the market.

The industry underneath them is still growing quickly. NAPHIA reported $6.2 billion of North American pet-insurance premiums in 2025, up 19.4% in a year, with 7.6 million pets insured. That leaves plenty of room because insurance penetration remains low relative to the overall pet population.

Hardware produces fewer large outcomes, but the winners can be bigger. Whisker has passed $300 million in annual revenue. Fi expects to cross $100 million of ARR. Tractive reached a $759 million acquisition value after building a subscription-backed GPS and health-monitoring business.

The dividing line is recurring revenue. A connected collar with years of subscription payments looks much better economically than a device sold once through retail. Pet insurance gets that recurring structure by default, while hardware companies have to build it.

Which Pet Tech startups are worth more than $500 million?

Only around half a dozen to ten Pet Tech companies can currently support a valuation above $500 million, depending on where we place the companies with estimated ranges.

Rover easily clears the line. Whisker, Loyal and Tractive sit well above it or around it with strong current evidence. Petvisor also appears comfortably capable of supporting a valuation in this territory given its $100 million-plus investment round and its reach across more than 10,000 veterinary clinics.

SantéVet, Petkit and Fi sit closer to the boundary because their current valuations require more inference. Fi's case has become much easier to defend lately because the company expects to cross $100 million of ARR and has expanded into 38 countries. A $500 million valuation at that revenue level would equal about 5x ARR.

Below that group, the market changes quickly. Lassie and Modern Animal are around $400 million. Petfolk is around the mid-$300 millions. Many other established Pet Tech startups fall below $300 million.

That makes $500 million a more useful dividing line than $1 billion for this sector. Reaching it already puts a company close to the top of Pet Tech.

Is Whisker really worth around $1 billion?

Whisker has one of the strongest cases for a roughly $1 billion estimated Pet Tech valuation because the company already generates more than $300 million in annual revenue.

Whisker says it employs more than 600 people and generates over $300 million a year. Its website also shows how large the installed base has become, with more than 2 million robots sold worldwide.

The trajectory matters more than the latest revenue number alone. Forbes reported around $180 million of Whisker sales in 2022, up from $150 million the year before. The company has therefore added well over $100 million of annual revenue since that earlier snapshot.

At $300 million of annual sales, a $900 million valuation implies roughly 3x revenue and $1.2 billion implies roughly 4x. Those multiples are demanding for consumer hardware, although Whisker has more going for it than a typical appliance manufacturer: proprietary products, a premium brand, direct customer relationships, consumables, accessories and an installed base that can upgrade over time.

Whisker has also reached this scale with surprisingly little outside funding. Pondera invested $31 million in 2019, far less capital than many companies worth only a fraction as much in our ranking.

For now, we would keep Whisker around the $900 million to $1.2 billion range rather than force a precise unicorn valuation that nobody has publicly disclosed.

Is Loyal already a billion-dollar Pet Tech startup?

Loyal is close enough to the $1 billion mark to belong in the conversation, but we would still treat a unicorn valuation as an estimate rather than an observed fact.

Loyal recently raised a $100 million Series C to advance LOY-002, its drug program aimed at extending healthy lifespan in senior dogs. The company has now raised more than $250 million and continues to clear important FDA milestones across its longevity programs.

This is a very different valuation story from Whisker or Fi. Loyal does not need $300 million of current consumer revenue to become extremely valuable if it gets a major veterinary drug approved and builds a new treatment category.

The trade-off is much higher technical risk. Clinical results, manufacturing, regulatory review and eventual adoption by veterinarians can all change the company's value quickly.

That is why an $800 million to $1.1 billion range makes more sense today than pretending Loyal has one precise value. The upside can justify the top end; the remaining drug-development risk keeps us from treating that figure like a completed transaction.

How big was Tractive's acquisition?

Tractive was acquired by Bending Spoons at a $759 million enterprise value, making the deal one of the largest proven Pet Tech exits below Rover.

This figure deserves clarification because larger numbers have circulated around the transaction. Bending Spoons itself later disclosed the $759 million enterprise value in its public-company reporting, which gives us a stronger anchor than secondary estimates around $900 million.

Tractive had already become a global subscription business before the acquisition. The company sells GPS trackers for dogs and cats and layers location, activity, sleep and health monitoring into a paid service. Before the deal, it had also acquired Whistle from Mars Petcare.

The capital efficiency is especially striking. Tractive had raised only a few tens of millions of dollars before selling for hundreds of millions.

For comparable companies such as Fi, Petkit and other connected-device businesses, the transaction provides a useful current benchmark: scaled hardware plus recurring subscription revenue can support a valuation well into the hundreds of millions.

Is Fi becoming as valuable as Tractive?

Fi is becoming one of the strongest independent Pet Tech hardware companies, but Tractive's $759 million sale still gives Tractive the higher proven valuation today.

Fi expects to cross $100 million in annual recurring revenue and has expanded into 38 countries, according to a recent Fortune interview with founder Jonathan Bensamoun. Those numbers are large enough to change how we should think about the company.

Fi is also extending the product technically. Its Fi Ultra uses Starlink direct-to-cell connectivity, giving dog owners another way to maintain location coverage beyond standard terrestrial networks.

Financially, Fi has taken a relatively disciplined path. The company has raised about $45 million in total and has gone years without needing another large venture round. That makes the growth more meaningful than if $100 million of ARR had required several hundred million dollars of financing.

Using roughly 4x to 6x ARR gives us a current valuation around $400 million to $600 million. Fi would need another major step in revenue, margins or strategic value to match Tractive's acquisition benchmark, but the gap is now small enough to take seriously.

Are veterinary software startups becoming one of the biggest Pet Tech categories?

Yes. Veterinary software now has enough funding, customers and product depth to rank among the most important parts of Pet Tech.

Petvisor gives us the clearest scale reference. Apax announced more than $100 million of new investment in the company and said Petvisor's software served over 10,000 veterinary clinics and 400 grooming facilities.

Digitail raised $23 million in Series B funding, taking its total investment above $37 million. Lupa raised $20 million in Series A funding only months after its seed round, bringing total funding to $25 million. The company says clinics using its software can save veterinarians around an hour per day.

AI has created another layer on top. Scribenote raised $8.2 million for an AI veterinary medical scribe. CoVet is building a veterinary copilot. Talkatoo focuses on dictation and documentation.

The customer base is also large enough to support several winners. Chewy disclosed that about 20,000 veterinary practices were enrolled in PracticeHub at the beginning of its current fiscal year, roughly half of U.S. veterinary clinics by Chewy's estimate.

Once software becomes embedded in records, payments, communication, pharmacy, scheduling and clinical work, switching becomes harder. That is the part of veterinary software investors are increasingly willing to pay for.

Why are Pet Tech veterinary clinic chains worth hundreds of millions?

Modern veterinary clinic chains can reach hundreds of millions of dollars in value because a successful network combines real healthcare revenue with digital retention and repeat visits.

Modern Animal gives us the cleanest example. Chewy completed the acquisition for $399.8 million. Before closing, Chewy said Modern Animal operated 29 clinics and would add more than $125 million of annualized run-rate revenue.

That puts the acquisition price at roughly 3.2 times annualized revenue. It is a meaningful premium, but still grounded in an operating healthcare business with physical clinics, veterinarians and recurring customer relationships.

Petfolk has followed a similar path. Its latest financing was a $40 million equity round, and available priced-round data puts the company around $359 million. Earlier funding rounds had already moved Petfolk from roughly the mid-$200 millions toward the $300 million range.

Vetic is scaling faster from a smaller base in India. The Economic Times reported FY2025 revenue of ₹66.6 crore, up from ₹26.5 crore the previous year, while the company now operates 65 clinics. Vetic recently raised another $40 million.

Clinic chains can therefore grow into large Pet Tech companies, although the economics remain more capital-intensive than software. Each new location needs people, equipment and real estate, so valuation ultimately depends on whether mature clinics produce attractive returns.

Are Pet Tech valuations backed by real revenue?

The top of Pet Tech is increasingly backed by real revenue, although biotech and early AI companies still depend much more heavily on future expectations.

Modern Animal is a useful anchor because both sides of the equation are visible: roughly $399.8 million of acquisition value against more than $125 million of annualized run-rate revenue. That works out to about 3.2x.

Whisker's estimated $900 million to $1.2 billion range implies roughly 3x to 4x its stated annual revenue. Fi's $400 million to $600 million estimated range corresponds to roughly 4x to 6x the $100 million ARR level it expects to cross.

Lassie's reported $400 million valuation also sits around 4x its approximately $100 million revenue reference. Those are meaningful multiples, although they are far below the extreme revenue multiples sometimes attached to fast-growing software companies.

Loyal and Gallant sit on another part of the spectrum. Their value can move sharply around clinical and regulatory milestones before commercial revenue becomes large. Gallant, for example, has received FDA-CVM progress on multiple investigational stem-cell therapies, including eligibility for an expanded conditional approval pathway.

There are also companies where historical funding gives a misleading impression of value. Wag! raised hundreds of millions over its life but trades or values far below that amount today. Bond Vet and several mobile-veterinary groups have also consumed substantial capital without ending up near the top of the valuation ranking.

So we give current revenue, ARR, completed transactions and recent priced rounds much more weight than cumulative funding when the evidence allows it.

Company	Current valuation reference	Revenue reference	Approximate multiple
Whisker	$900M–$1.2B estimated	$300M+ annual revenue	~3x–4x
Tractive	$759M acquisition EV	substantial subscription business	transaction anchor
Lassie	about $400M	about $100M revenue reference	~4x
Modern Animal	$399.8M acquisition	$125M+ annualized run rate	~3.2x
Fi	$400M–$600M estimated	approaching $100M ARR	~4x–6x
Petvisor	$550M–$850M estimated	10,000+ clinics served	operating-data estimate
Loyal	$800M–$1.1B estimated	pre-commercial drug economics	pipeline-driven

How concentrated are Pet Tech startup valuations?

Pet Tech valuation is heavily concentrated: the top ten companies in our 97-company dataset account for roughly half of the total value we estimate across the whole ranking.

Using the midpoint of each valuation range, the 97 companies add up to roughly $15 billion to $16 billion of combined value. The first ten alone account for around $8 billion.

Extending the calculation through the top twenty gets us to roughly three-quarters of the entire valuation pool. The remaining 77 companies share only about one-quarter.

The drop becomes obvious as we move through the ranking. Companies near the top are worth hundreds of millions or billions. Around the middle, valuations tend to fall into the tens of millions. By the bottom, several businesses are worth only a few million dollars based on the evidence we can find.

Counting startups can therefore give the wrong impression of market size. Pet Tech has a long tail of companies, but most of the financial value sits in a small group.

What kinds of Pet Tech startups get the highest valuations?

The highest Pet Tech valuations currently cluster around recurring pet spending: veterinary care, insurance, marketplaces, subscription-backed hardware and veterinary software.

Rover represents the marketplace model at the top. Whisker, Tractive and Fi show that connected hardware can become much more valuable once the company builds a strong brand, a large installed base or recurring subscription revenue.

SantéVet, Lassie and ManyPets show the attraction of insurance. Premiums repeat every year, and penetration remains low enough to leave room for growth.

Veterinary care adds another layer because the spending is both recurring and difficult to postpone. Modern Animal, Petfolk and Vetic can capture consultation, diagnostics, pharmacy and follow-up revenue around the same customer relationship.

Software sits slightly differently. A clinic may start by buying scheduling or communication tools, but the more a platform touches records, payments, pharmacy and clinical work, the harder it becomes to replace. That can support software-like margins without needing a mass consumer audience.

The strongest business models are not necessarily the flashiest ones. They tend to sit close to spending that pet owners already make repeatedly and then use technology to take a larger share of it.

How large is the Pet Tech market today?

There is no single clean Pet Tech market-size number because the category cuts across veterinary care, insurance, devices, software, marketplaces and biotech. The underlying pet economy is much larger than the startup valuations in this ranking.

The American Pet Products Association currently puts U.S. veterinary care and product sales at about $41 billion and projects total U.S. pet-industry sales of roughly $165 billion. NAPHIA separately reports $6.2 billion of pet-insurance premiums across North America.

Even the narrower connected-device category is becoming meaningful. Fortune cited a pet-wearables market of about $3.8 billion in 2026 while reporting on Fi's expansion.

That is why the $15 billion to $16 billion of combined estimated startup value in our dataset should not be confused with the size of the Pet Tech economy. The startups are only one layer sitting on top of much larger pools of pet spending.

Is AI changing Pet Tech valuations?

AI is changing Pet Tech, but it has not yet displaced healthcare, insurance, marketplaces or subscription hardware at the top of the valuation table.

The clearest adoption is inside veterinary software. Digitail is adding AI to practice management, Lupa is building AI agents into its clinic operating system, and Scribenote automates medical documentation. These products attack expensive staff time rather than trying to invent a new consumer habit.

That makes veterinary AI easier to justify economically. If a tool saves a veterinarian an hour a day, improves documentation or lets a clinic handle more patients, the buyer can connect the software directly to labor capacity and revenue.

AI also appears in insurance automation, health monitoring and diagnostics, but most of those companies are still too small or too early to carry the market's largest valuations. Right now, AI looks more like an accelerant inside strong Pet Tech business models than a category that automatically commands a premium on its own.

Can smaller Pet Tech startups still become valuable?

Yes, but the path is narrower than the long company list makes it look. Most smaller Pet Tech startups will not reach hundreds of millions of dollars in value simply by shipping a useful pet product.

The better paths usually involve a wedge that can expand. A clinic tool can move into payments or pharmacy. A tracker can add health monitoring and subscriptions. An insurer can layer prevention and care services on top of the policy. A marketplace can deepen supply and demand without owning much physical infrastructure.

Smaller companies also have one advantage: they do not need to compete with Rover or Whisker on absolute scale to create a good outcome. A $50 million or $100 million acquisition can still be meaningful if the business was built with modest funding.

Capital discipline matters a lot here. Pet Tech has several examples where a company raised heavily but ended up with a much weaker valuation than the funding history once suggested.

Does raising more money mean a higher Pet Tech valuation?

No. Funding and valuation are related, but Pet Tech gives us plenty of examples where cumulative capital says very little about current value.

Tractive is the cleanest counterexample near the top. It sold for $759 million after raising only a few tens of millions of dollars. Whisker also reached more than $300 million of annual revenue with relatively little outside capital compared with many venture-backed companies.

On the other side, businesses can raise hundreds of millions and still end up worth far less if growth slows, public markets reprice the company or the operating model remains expensive. Wag! is the obvious reminder that historical funding is not a floor under valuation.

For this ranking, recent transactions, priced rounds, revenue, ARR and operating scale are therefore much more useful than a simple "total funding raised" column.

What does the Pet Tech valuation ranking tell us overall?

Pet Tech is already a real multi-billion-dollar startup category, but it is much more concentrated and much more healthcare-heavy than the phrase "pet technology" suggests.

Rover is still in a class of its own at $2.3 billion. Below it, Whisker and Loyal sit around the billion-dollar threshold, Tractive provides a hard $759 million transaction benchmark, and then the market falls into a broad group of companies worth a few hundred million dollars.

The most valuable businesses are usually attached to recurring spending. That can mean pet sitting, insurance premiums, veterinary visits, software subscriptions, connected-device memberships or eventually veterinary drugs.

The ranking also rewards proof. A completed acquisition or priced financing deserves more confidence than a valuation inferred from revenue, and a company with $100 million of ARR deserves more confidence than one valued mainly on a future market narrative.

So the strongest Pet Tech companies today are not simply the ones with the cleverest gadgets. They are the ones that have found a repeatable way to sit inside the everyday economics of pet ownership.